Regorafenib in Combination with TAS-102 in subjects with metastatic colorectal cancer who have progressed after standard therapy: A multicenter Phase I study.
Laufzeit: 01.01.2016 - 31.12.2020
Kurzfassung
This is a multicenter, open-label, non-randomized, dose-escalation Phase I study evaluating the safety and anti-tumor activity of TAS-102 administered in combination with Regorafenib in patients with metastatic colorectal cancer.
